Xaira Therapeutics
PrivateLast Round
Series A
Apr 23, 2024
Est. Valuation
$2.7B
Total Funding Raised
$1B
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Xaira Therapeutics is a biotechnology company that leverages artificial intelligence to enhance drug discovery and development through comprehensive product development and data generation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Foundation
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Xaira Therapeutics Comparables
Compare Xaira Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Insitro | 87% | |
| Valo Health | 83% | |
| Generate Biomedicines | 83% |
For institutional investors. Book with your work email.
Xaira Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 23, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Xaira Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Breyer Capital | Series A |
| SV Angel | Series A |
| New Enterprise Associates | Series A |
| F-Prime Capital | Series A |
| WRF Capital | Series A |
| Risk and Return | Series A |
| Parker Institute for Cancer Immunotherapy | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 123% MoM, reaching 47.1K.
- Jun 21, 2026
Developing a next-generation Vision AI platform for autonomous labs.
For institutional investors. Book with your work email.
Xaira Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Xaira Therapeutics's valuation, stock price, and market status.
Is Xaira Therapeutics a public or private company?
Xaira Therapeutics is a private company.
What is the current stock price of Xaira Therapeutics?
Xaira Therapeutics is a private company, so its shares have no public market price. Caplight tracks Xaira Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Xaira Therapeutics worth (valuation)?
Xaira Therapeutics's valuation is estimated at $2.7B based on funding round data.
Can I buy Xaira Therapeutics stock?
Xaira Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Xaira Therapeutics's last funding round?
Xaira Therapeutics's most recent funding round was Series A on April 23, 2024.
Who are the main investors in Xaira Therapeutics?
Key investors in Xaira Therapeutics include ARCH Venture Partners, Foresite Capital, Foresite Labs.
Will Xaira Therapeutics IPO soon?
No public IPO plans have been announced for Xaira Therapeutics.
How can I track Xaira Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Xaira Therapeutics's shares on secondary markets.